Skip to content

Rhenium/Yttrium-Skin Cancer Therapy for the Treatment of Non-Melanoma Skin Cancer

Efficacy of Personalized Irradiation with Rhenium/Yttrium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210612051548N6
Enrollment
20
Registered
2023-05-24
Start date
2023-07-06
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-melanoma Skin Cancer. Other and unspecified malignant neoplasm of skin

Interventions

Intervention group: Patients 18 years and older with stage I or II BCC (Basal Cell Carcinoma) or SCC (Squamous cell carcinoma).

Sponsors

Boushehr University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >=18 years Stage I or II BCC (Basal Cell Carcinoma) or SCC (Squamous Cell Carcinoma) Confirmed Histology (with depth of lesion noted) Subjects with up to 3 lesions suitable to enter the study (subjects with more than 3 lesions are not excluded from the study, however 3 target lesions are determined for study evaluation only.) Subjects able and willing to comply with the requirements of the study Lesions with a depth up to 3mm confirmed on biopsy report AND deemed appropriate clinically by treating clinician Subjects who are not deemed suitable for surgery, for example due to tumour location, performance status or other comorbidities as deemed relevant by the treating clinician Patients who may have declined Surgery and/or fractionated Radiation Therapy

Exclusion criteria

Exclusion criteria: Inability to personally provide written informed consent or to understand and collaborate throughout the study Inability or unwillingness to comply with study requirements Prior treatment with surgery or radiation therapy for their target lesion(s) Depth of lesion greater than 3mm as defined by Biopsy and/or clinical assessment Lupus and Scleroderma Prior laser at the tumour site Malignant melanoma systemic therapy ongoing Any ongoing treatment for malignancy, or in the last 4 weeks prior to study entry A tumour affecting nerves or bony structures pregnancy's and/or Lactation Anatomical exclusions: NMSC's of the Medial canthus, eyelid margin (upper and lower), Vermillion lip

Design outcomes

Primary

MeasureTime frame
The longest diameter of the lesion. Timepoint: 6 months. Method of measurement: Visual RECIST (Response Evaluation Criteria in Solid Tumours) tool.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Assadi

Boushehr University of Medical Sciences

assadipoya@yahoo.com+98 77 3332 0361

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026